(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

DIA Global Center

Oct 28, 2019 8:15 AM - Oct 29, 2019 4:30 PM

21 Dupont Circle NW, Suite 300, Washington, DC 20036

Regulatory Affairs for Combination Products

Learn about FDA's approach to regulation of combination products, the processes to streamline development of single entity, and aligning requirements between drugs and devices.

Register

Overview

This introductory course will provide learners with an overview of FDA’s approach to regulation of combination products including review of FDA’s recent guidance. Topics will cover processes to streamline and integrate development of single entity, co-packaged and cross-labeled products. Discussion will cover approaches to aligning requirements between drugs and devices and assuring successful human factors interface. Course material will address FDA’s expectation for post-marketing activities, including safety reporting and manufacturing modifications. Workshops will offer practical applications in when and how to report as a constituent product or as a combination.

Can't attend this course?  Join us in 2020:  Washington, DC in October!

 

What you will learn

  • GMP compliance
  • Post-marketing safety
  • Post-approval changes
  • Streamlining device and drug systems
  • Specifications and design control
  • Risk assessment and management
  • Human factors interface

Who should attend?

This course is designed for professionals in:

  • Regulatory affairs
  • Clinical affairs
  • Quality assurance
  • Manufacturing and CMC
  • Safety and pharmacovigilance
  • Project management

Learning objectives

At the conclusion of this course, participants should be able to:

  • Explain the similarities and differences in drug and device regulations
  • Identify opportunities to streamline single entity compliance by integrating drug and device systems
  • Discuss risk assessment and management in the combination product environment
  • Describe the unique requirements of successful combination product development
  • Explain FDA expectations of combination product applicants and how to work successfully with the agency
  • Discuss how human factor considerations are assessed and controlled in the drug/device user interface

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

Have an account?

Register

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.